







an Open Access Journal by MDPI

# **Cancer Stem Cells and Therapy Resistance**

Guest Editor:

### Dr. Saroj K. Basak

Division of Pulmonary & Critical Care, Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095-1690, USA

Deadline for manuscript submissions:

closed (31 December 2020)

## Message from the Guest Editor

Cancer stem cells (CSCs) are an integral part of cancer origin and progression resulting in tumor heterogenicity. Tumor heterogenicity is characterized by different types of cancer cells in tumor that are, in turn, characterized by differential cell-surface marker expression, genetic and epigenetic changes, and their different cellular function. Tumor heterogenicity arises from the interaction of tumor cells with a tumor microenvironment that includes intrinsic and external factors. The CSCs are also notorious for drug/therapy resistance and are prone to changes due to therapeutic pressure, leading to tumor progression, metastasis, and tumor recurrence.

To better target cancer therapies, we must understand the biology of CSCs and develop novel therapeutic strategies that can target CSCs more efficiently. This Special Issue examines molecular and cellular factors in the tumor microenvironment that cause CSC survival and therapy resistance, and discusses new strategies to improve CSC-targeted therapies.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**